Drugmakers curb Swiss reimbursement submissions amid US international drug-pricing concerns

Interpharma says seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for Swiss reimbursement, as companies consider the potential implications of Swiss prices for the US market.

A survey by Swiss pharmaceutical industry association Interpharma found that seven of 22 new innovative medicines introduced between January 2025 and June 2026 were not submitted for inclusion on Switzerland’s reimbursement list, compared with an average of 24 submissions during equivalent 18-month periods between 2019 and 2025.

Interpharma attributes the reduction partly to concerns that lower Swiss prices could influence US pricing under international benchmarking policies, creating a potential tension between pharmaceutical pricing strategy and timely Swiss patient access.

Field	Content
Alert Type	Industry Update
Topic	Pricing; reimbursement; market access
Organisation(s)	Interpharma; Swiss Federal Office of Public Health (FOPH)
Affected Stakeholders	Pharmaceutical companies launching innovative medicines in Switzerland; Swiss patients; payers and market-access teams
Geography	Switzerland; United States
What Happened	Interpharma reported on 13 August 2026 that seven of 22 new innovative medicines introduced between January 2025 and June 2026 were not submitted for Switzerland’s reimbursement list, which determines coverage under mandatory health insurance and establishes reimbursed prices. A further three medicines were not submitted for Swiss marketing approval. Interpharma linked the pattern to pharmaceutical companies’ concerns over the potential effect of Swiss pricing on US prices under the US administration’s most-favoured-nation pricing approach. The 15 medicines submitted for reimbursement compare with an average of 24 during equivalent 18-month periods between 2019 and 2025. (Global Banking & Finance Review)
Why It Matters	Inclusion on Switzerland’s Specialities List is important for broad access through mandatory health insurance. If manufacturers delay or avoid reimbursement applications because of the potential consequences of Swiss prices for larger markets such as the US, international reference-pricing policies could indirectly affect launch sequencing and patient access outside the country implementing the policy. The reported figures are based on an industry survey, however, and do not establish that US policy was the sole cause of every individual decision. (Global Banking & Finance Review)
Supporting Context	Switzerland’s FOPH assesses medicines for inclusion on the Specialities List and sets reimbursed prices. Swiss price-setting itself uses both an internal comparison with medicines for the same indication and an external comparison drawing on prices in nine European countries. (Federal Office of Public Health)
Who Is Most Affected	Pharmaceutical market-access and pricing teams face the most direct strategic issue because decisions on Swiss reimbursement may now need to consider potential international pricing consequences. Swiss patients are also directly affected where medicines are approved but not submitted for reimbursement, because routine access through mandatory health insurance may be unavailable, although reimbursement can be possible in qualifying individual cases. (Global Banking & Finance Review)
Industry Impact	The findings suggest international price referencing can influence not only medicine prices but also the order and timing in which manufacturers seek reimbursement across countries. If the pattern persists, smaller European markets used as international pricing benchmarks could face greater launch and reimbursement delays as manufacturers seek to manage the potential effect on prices in commercially larger markets.
Key Takeaway	Interpharma’s findings suggest US international drug-pricing policy is becoming a consideration in Swiss launch and reimbursement decisions, with potential consequences for patient access and pharmaceutical market-access strategy.
What to Watch	Whether reimbursement submissions remain below historical levels, how manufacturers sequence future Swiss and US launches, and whether Switzerland or the US modifies pricing policies in response to concerns about their effects on medicine availability.
Primary Source	Interpharma survey, reported 13 August 2026
Relevant Date	13 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com